Gnosis by Lesaffre (formerly Lesaffre Human Care), business unit of Lesaffre Group dedicated to nutrition, health and personal care businesses, is raising awareness about ibSium with the launch of a website dedicated to its patented ingredient. The company opted for the online platform as a way to expand its reach and increase ibSium's visibility worldwide.
"This website was designed with the user experience in mind and offers a clean layout, simple navigation and a way for users to contact us with ease, directly from the page. We are inviting visitors to explore it and discover the numerous benefits of ibSium for intestinal health as well as learn more about the substantial science behind this unique strain of Saccharomyces cerevisiae," said Elodie Ruffin, Probiotics Product Manager at Gnosis by Lesaffre.
Elodie Ruffin expects the new site, found at www.ibsium.com, to be of interest for product developers and ingredients purchasers, as it offers detailed information about the ingredient itself, clinical data and practical advice on how to use it to alleviate occasional intestinal pain, bloating and constipation.
With Gnosis by Lesaffre strong emphasis on providing world-class scientific and clinical data on its ingredients, this new website is also a way for visitors to stay informed of the latest research results and peer-review publications on ibSium.
What is ibSium?
ibSium is the brand name of Saccharomyces cerevisiae CNCM I-3856, an exclusive strain of yeast patented by Lesaffre. This innovative ingredient is used in a wide range of dietary supplements developed by the company's partners since 2010 and already widely prescribed by doctors and gastroenterologists.
The science around this ingredient supporting intestinal comfort, showed it may improve the quality of life of billions of people worldwide affected by painful digestive disorders or complaining about some gut-related symptoms.
It has demonstrated that it may improve intestinal pain, bloating and constipation through several clinical studies1,2 and the findings of a meta-analysis investigating ibSium's health benefits, published in the renowned peer-reviewed journal 'World Journal of Gastroenterology'3. A large-scale study run by prescribing physicians in over 1160 volunteers presenting symptoms of IBS has also proven ibSium to be safe, fast-acting (less than 15 days) and well-tolerated, inducing no side-effects or habituation.
References
1. Pineton de Chambrun G, Neut C, Chau A, Cazaubiel M, Pelerin F, Justen P, Desreumaux P. A randomized clinical trial of Saccharomyces cerevisiae versus placebo in the irritable bowel syndrome. Digestive and Liver Disease; 2015 February; 47(2):119-124
2. Spiller RS, Pélerin F, Cayzeele Decherf A, Maudet C, Housez B, Cazaubiel M, Justen P. Randomized double blind placebo-controlled trial of Saccharomyces cerevisiae CNCM I-3856 in Irritable Bowel Syndrome: improvement in abdominal pain and bloating in those with predominant constipation. United European Gastroenterology Journal, published online before print August 21, 2015.
3.Cayzeele-Decherf A, Pélerin F, Leuillet S, Douillard B, Housez B, Cazaubiel M, Jacobson GK, Jüsten P, Desreumaux P. Saccharomyces cerevisiae CNCM I-3856 in irritable bowel syndrome: an individual subject meta-analysis. World J Gastroenterol 2017;23(2):336-344.
